Amrixa Pharmaceuticals is focused on
building novel mRNA-LNP therapies
for poorly treated diseases.
We’re incubating at BioLabs LA @ The Lundquist Institute, where we are engaged in animal
studies for our lead therapeutic, RXA-2. We completely own our IP; that includes novel
mRNA sequences, manufacturing methods, and a proprietary LNP platform. We are open
to exploring partnerships, licensing, and investment offers.